New Delhi: Drugs Controller General of India (DGCI) approves emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b, ‘Virafin’ for treating moderate COVID19 infection in adults.
In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections.
Comments are closed.